INTRODUCTION
Sarcoidosis is a chronic, multisystem granulomatous disorder that commonly involves the lungs and lymph nodes [1] , but can involve all other organ systems. The disease is thought to affect 10 per 10 000 white Americans and 35 per 10 000 African-Americans [2] . Yet, up to 80% of patients will require treatment [2] , and nearly half those who require systemic therapy will still require therapy 5 years after the diagnosis [3] . Since 1951, corticosteroids have been the first line of therapy for patients with symptomatic and progressive disease, but its use, although effective in the short-term, has been limited as a long-term therapy by dose-dependent side effects and a lack of evidence that it favorably alters the natural history of progressive disease [4 & , [5] [6] [7] .
Recent evidence suggests that, despite the widespread use of corticosteroids and other immunosuppressants, mortality rates in sarcoidosis have been steadily increasing [8] . Between 1998 and sarcoidosis-associated mortality rates increased. They increased more than 50% among women and 30% among men, with an average yearly increase of 3% from 1988 to 2007 [8] . Interestingly, although the greatest relative increase in ageadjusted mortality occurred in non-Hispanic whites compared with non-Hispanic backs, the greatest absolute increase was seen among non-Hispanic black women. The most common cause of death cited in this study was the disease process itself, pointing to the need for more effective therapies for progressive disease [8] (Fig. 1) .
Sarcoidosis pathogenesis begins when an as of yet unidentified antigen is processed by antigenpresenting cells and presented to T-lymphocytes in the context of major histocompatibility complex (MHC) class II surface molecules. The interaction leads to the activation of an inflammatory response with a decidedly Th1 bias, the recruitment of inflammatory cells, and the formation of noncaseating granulomas. More recently, there is compelling evidence for a role of Th17 immune pathways in the generation and maintenance of sarcoidosis granulomas. The prevailing hypothesis is that antigen persistence leads to augmentation and persistence of the inflammatory cascade (with the elevation of tumor necrosis factor), whereas antigen clearance is followed by termination of the inflammatory cascade and disease remission [9] .
The decision to initiate chronic immunosuppression for patients with sarcoidosis is often predicated on a number of factors. It may be based on the type of organ involvement (symptomatic cardiac, neurologic, or progressive hepatic disease), whether they are persistently symptomatic on corticosteroids, or whether they are likely to require a long duration of therapy (chronic active disease with advanced organ damage). The Scadding stage of disease correlates loosely with the risk of chronic disease and likelihood for the need for chronic therapy. Those patients who have experienced a pattern of relapsing-remitting disease (often with months or years between relapses) may benefit by chronic immunosuppression to prevent further relapses. Based on these observations, patients can be classified in terms of disease activity as having disease in remission (spontaneous remission may be the norm), acute sarcoidosis (with or without Lofgren's syndrome), transiently active disease (usually remits within several months), chronic progressive disease (requiring chronic immunosuppression to prevent organ damage), or relapsingremitting disease (requiring chronic immunosuppression to prevent disease relapse). In our opinion, those with chronic progressive disease and with relapsing-remitting disease most often progress to severe end-organ damage despite chronic immunosuppression. Once the decision to proceed with chronic therapy is made, the next challenge is the choice of agent and the duration of immunosuppression. A recent Delphi study of sarcoidosis experts demonstrates the general lack of consensus and of data to support this decision process [10] .
Corticosteroids have been shown to offer shortterm benefits (in symptoms, pulmonary function, and radiographically), but early studies suggest that it offers no long-term benefit (radiographically or by pulmonary function testing) compared with placebo [11] . The use of corticosteroid-sparing agents (such as antimetabolites) has improved the treatment options available to patients, but not all benefit from this therapy and some experience adverse effects requiring cessation of therapy [12] . With the emergence of many other biologics targeting specific molecules in the inflammatory cascade, there is a burdening need to explore them as potential therapies for patients with sarcoidosis. There is also a need to develop new therapeutic approaches with the intent of modifying the natural history of active progressive and relapsing-remitting disease, that is, a need for disease modifying antisarcoidosis drug therapies.
IMMUNOPATHOGENESIS OF SARCOIDOSIS
Alveolar macrophages, activated via an aerosol antigen, play a fundamental role in the pathogenesis of sarcoidosis. Alveolar macrophages from patients with sarcoidosis are increased and spontaneously produce tumor necrosis factor that is thought to be the granuloma-promoting factor in sarcoidosis [9] . Antigen processing and presentation by macrophages, primarily via the human leukocyte antigenantigen D related (HLA-DR) MHC class II cell surface receptor, leads to T-cell activation that is necessary for granuloma formation and maintenance. This Tcell activation has several important characteristics. First, T-cell activation by activated macrophages depends on costimulatory signaling from the macrophage's CD80 and CD86 which attaches to the T-cell protein receptor cytotoxic T-lymphocyte associated protein 4 (CTLA-4). This T-cell response is biased toward Th1 cytokine release including interleukin (IL)-6 and IL-12. Second, Th17 cells are also increased in sarcoidosis and may play a role in granuloma formation and maintenance, which
indicates an important role for IL-17 and IL-23. Finally, the p38 mitogen-activated protein (MAP) kinase tumor necrosis factor signal transduction pathway is dysregulated in sarcoidosis, which leads to excessive Th1 and Th17 immune response, including additional TNFa production [13] . Potential biologic targets for novel sarcoidosis therapies include T-cell activation, Th1-mediated inflammation, Th17-mediated inflammation, and tumor necrosis factor signal transduction pathways such as the p38 MAP kinase (Fig. 2) .
ANTIMETABOLITES: METHOTREXATE, AZATHIOPRINE, LEFLUNOMIDE, AND MYCOPHENOLATE
Among the most utilized steroid-sparing agents, the antimetabolite methotrexate has been shown in a randomized placebo-controlled clinical trial to be an effective therapy for sarcoidosis that allows patients to reduce or completely withdraw systemic corticosteroid therapy [14] ( Table 1) . Developed as a folate analogue that inhibits dihydrofolate reductase, its anti-inflammatory effects appear to be related to extracellular adenosine release causing inhibition of IL-8 production, IL-6 secretion, and LTB4 synthesis by inflammatory cells [15] . Methotrexate's efficacy has been limited by its highly variable oral bioavailability, and there are concerns about its New molecular targets for the treatment of sarcoidosis Chiarchiaro et al.
adverse effects on the liver and lungs. Azathioprine, a prodrug of mercaptopurine, halts DNA replication and therefore exerts its inhibitory effects on proliferating cells such as lymphocytes [16] . Azathioprine has been found to have similar efficacy as a therapy for sarcoidosis, although the data are more limited [15] and it is discontinued more often than methotrexate due to adverse side effects [16, 17] . Leflunomide exerts its immunomodulatory effects by inhibiting mitochondrial dihydroorotate, thereby inhibiting urinidine monophosphate synthesis and cell cycle progression. It has been shown to significantly improve lung function in combination with methotrexate or, occasionally, as monotherapy in patients who do not respond to or tolerate methotrexate therapy [18, 19] . Mycophenolate mofetil is an inhibitor of inosine-5-monophosphate dehydrogenase and depletes guanosine nucleotides preferentially from T and B lymphocytes inhibiting proliferation. It has been shown to be useful in case series for those who are intolerant of other steroid-sparing agents, but a recent single-center trial questions its efficacy in sarcoidosis [20, 21] .
TNFa INHIBITORS: INFLIXIMAB, ADALIMUMAB, AND NONTARGETED TUMOR NECROSIS FACTOR AGENTS
For patients with systemic disease that is refractory to glucocorticoids or antimetabolites, targeted TNFa inhibition is the next recommended step in treatment [9, 13] . The best data are for infliximab, which has shown mixed results in two randomized clinical trials [22, 23] . Efficacy data on adalimumab is limited to a single, small open-label study [24] . It may be an effective alternative for patients intolerant to infliximab, showing similar safety and efficacy results [24, 25] , but the data are limited. Thalidomide, pentoxifylline, and apremilast are three drugs with nontargeted TNFa inhibitory effects and are considered third line because of disappointing data on efficacy and side effects [26] [27] [28] .
CYTOTOXIC T-LYMPHOCYTE ASSOCIATED BLOCKADE
T-cell activation requires costimulation through connection between the macrophage's CD80/ CD86 complex and the CTLA protein receptor on the T cell. Blockade of this connection results in downregulation of the T-cell response. Abetacept is a fusion protein composed of the Fc region of the IgG1 fused to the extracellular domain of CTLA-4 that binds to the CD80 and CD86 molecule. This prevents costimulation and results in T-cell downregulation. Abetacept is currently approved for patients with rheumatoid arthritis who have had an inadequate response to anti-TNFa therapy. Several placebo-controlled trials have been conducted on abetacept in Crohn's disease and ulcerative colitis [29] . This drug could be a potentially useful immunosuppressant in patients with sarcoidosis.
INHALED VASOACTIVE INTESTINAL PEPTIDE
Vasoactive intestinal peptide (VIP) is a neuropeptide that has pleiotropic effects on smooth muscle contractility and vasodilation as well as anti-inflammatory effects. Inhaled VIP has been shown to have immunoregulatory effects in sarcoidosis, including an increase in regulator T cells resulting in suppressed induction and proliferation of effector T cells and downregulation of HLA-DR, CD86, and CD8 þ in bronchoalveolar lavage (BAL) specimens in patients with sarcoidosis [30] . VIP therapy is being explored in a number of inflammatory diseases including sarcoidosis. 
EXISTING Th1-TARGETED THERAPIES
There are existing therapies aimed at damping Th1-mediated inflammation through tumor necrosis factor inhibition that have been tested in sarcoidosis. Infliximab is discussed above. Adalimumab has shown therapeutic efficacy in small cohort studies [31] . Golimumab and etanercept are similar agents that have both been shown to be ineffective in sarcoidosis [32, 33] .
IL-6
IL-6 is an important proinflammatory cytokine secreted by T cells and macrophages that stimulates an immune response leading to granuloma formation. Takizawa et al. [34] demonstrated early on that IL-6 levels were elevated in the BAL fluid of patients with sarcoidosis and correlated strongly with levels of BALF CD3 þ lymphocytes. Treatment with corticosteroids led to a significant reduction in the levels of IL-6 cells in this population. The first biologics against IL-6 approved by the Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis were tocilizumab (ACTEMRA; Genentech, San Francisco, California, USA), an anti-IL-6 receptor blocker, and siltuximab, an antibody directed against IL-6 itself. Olokizumab is a human mAb directed at IL-6 that has shown promising results in a randomized phase II study for patients with moderate-to-severe rheumatoid arthritis [35] . There are a number of therapies directed against IL-6 in early development for autoimmune diseases. However, therapies directed against IL-6 or IL-6 receptor have not been studied in patients with sarcoidosis.
IL-12/IL-23P40 AND Th17 PATHWAYS
IL-12/IL-23 is a heterodimeric cytokine composed of the IL-12p40 minor subunit and the IL-23p19 major subunit. IL-12 is a Th1 cytokine produced by macrophages, among other cells, in response to antigenic stimulation and is involved in the differentiation of naïve T cells into Th1 cells. It also stimulates the production of TNFa. The p40 minor subunit of IL-12 (IL-12p40) is elevated in BAL samples from patients with sarcoidosis compared with idiopathic pulmonary fibrosis patients and controls [36] . Gene expression profiles comparing sarcoidosis lesional skin biopsies with nonlesional biopsies and normal controls identified a number of dysregulation genes including IL-12p40 and IL23 receptor, suggesting a role of both Th1 and Th17 pathways in sarcoidosis. Similarly, Ten Berge et al. [37] and Facco et al. [38] both showed elevated levels of IL-17a þ cells in the BAL fluid of patients with sarcoidosis compared with peripheral blood and healthy volunteers and found IL-17a þ T cells within tissue granulomas, indicating a role for Th17 pathways in the induction and maintenance of sarcoidosis granulomas.
There are a plethora of drugs targeting molecules in the Th17 inflammatory pathways. Ustekinumab is a human mAb that binds to the p40 minor subunit of IL-12 (a Th1 cytokine) and IL23 and was recently approved for the treatment of psoriatic arthritis and moderate-to-severe plaque psoriasis. The efficacy of ustekinumab was recently studied in patients with chronic pulmonary sarcoidosis and/or skin sarcoidosis and found to be ineffective in patients with sarcoidosis [33] . However, this lack of effectiveness is at first perplexing as IL-12 is a relevant Th1 cytokine in sarcoidosis. One hypothesis that might explain the findings is that targeting the p40 minor subunit may be less effective than targeting the major subunit of the IL-23 heterodimer complex (IL-23p19). Like IL-12/IL-23p40, IL-23p19 mRNA expression has also been shown to be elevated in sarcoidosis skin lesions [39] . Novel therapies, targeting the major subunit of IL-23, are approved and may provide another opportunity to explore this mechanism. For example, STA 5326 is a potent inhibitor of IL-12/23 production and has been tested in phase I/II studies for moderate-to-severe Crohn's disease and rheumatoid arthritis with mixed results [40, 41] . Tildrakizumab, a mAb that blocks IL-23, is in phase III clinical trials for psoriasis, and secukinumab, a recent FDA-approved human mAb targeting IL-17 for plaque psoriasis, has yielded promising results in rheumatoid arthritis [42] and ankylosing spondylitis [43] . None of these drugs have been studied in sarcoidosis.
P38 MITOGEN-ACTIVATED PROTEIN KINASES, NLRP3 INFLAMMASOME, AND THE UBIQUITIN PROTEASOME SYSTEM
There is a strong link between the p38 group of MAP kinases and production of TNFa [13] . Enhanced p38 activation leads to excessive Th1 and Th17 proinflammatory cytokine production. When BAL cells of sarcoidosis patients are stimulated by sustained p38 phosphorylation, they have been shown to respond with more robust TNFa and IL-12/IL-23p40 production [13] . Targeting p38 MAP kinases has appealing therapeutic potential as it plays an important role both in maintaining tumor necrosis factor mRNA stability as well as in the downstream activation of a variety of cytokines that result from tumor necrosis factor signaling. BIRB 796 and semapimod are p38 MAP kinase inhibitors that have undergone clinical trial testing in Crohn's disease, but neither has been studied in sarcoidosis [44, 45] .
First recognized in 2002, inflammasomes are newly recognized pattern-recognition receptors expressed on immune and inflammatory cells that target endogenous and exogenous pathogens. Numerous inflammasomes have been identified, but the best studied is the NLRP3 inflammasome. Activation of this protein complex leads to the activation of caspase-1 and release of the proinflammatory cytokine IL-1b that is involved in both acute and chronic inflammatory responses in a variety of inflammatory diseases including sarcoidosis. Several NLRP3 inhibitors have been approved: rilonocept, an IL-1 blocker for cryopyrin-associated periodic syndrome (CAPS); canakinumab, a mAb inhibitor of IL-1b for CAPS; and anakinra, an IL-1 receptor antagonist for rheumatoid arthritis and CAPS. None have been studied in sarcoidosis [46] [47] [48] .
The ubiquitin proteasome system (UPS) is a highly regulated component in cells that controls protein degradation and abundance, and therefore regulates many cellular activities and functions [49 & ]. Specifically, protein ubiquitination occurs through the activity of protein complexes consisting of ubiquitin protein, the E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, and E3 ubiquitin ligase. The majority of ubiquitinated proteins are degraded by the 26S proteasome [49 & ,50] . Interestingly, several components of the UPS, such as E3 ubiquitin ligases, play critical roles in tissue inflammation. For example, patients with mutation of the anti-inflammatory ubiquitin E3 ligase ITCH suffer from syndromic multisystem autoimmunity, inflammatory lung disease, and premature death [51, 52] . Also, the major inflammatory signaling pathway, NF-kB activity, is directly regulated by UPS. Many efforts have been made to develop therapeutics targeting components of UPS; however, the only FDA-approved drugs so far are the three 26 proteasome inhibitors -Bortezomib (Millennium Pharmaceuticals, Cambridge, Massachusetts, USA), Carfilzomib (Onyx Pharmaceuticals, Inc., Thousand Oaks, CA, USA), and Ixazomib (Milleneium Pharmaceuticals, Cambridge, MA, USA) [53] . Although all these proteasome inhibitors are only approved for multiple myeloma, many studies had investigated their efficacies in inflammatory diseases. For example, bortezomib and carfilzomib have been shown to be effective in inflammatory models of respiratory syncytial virus infection, muscle wasting in diabetes, adjuvantinduced arthritis, intracerebral hemorrhage, sepsis, acute graft-versus-host diseases, ischemiareperfusion injury, and acute pancreatitis-induced lung injury [54, 55, 56 & , [57] [58] [59] . Moreover, carfilzomib has recently been tested in a clinical trial for antibody-mediated rejection in lung and heart transplant [60] . These proteasome inhibitors hold potential as novel therapies for sarcoidosis.
CONCLUSION
Although there have been significant advances in the understanding and treatment of sarcoidosis, the disease continues to exert an unacceptable burden in terms of morbidity and mortality. Rising mortality from the disease strongly supports the need to develop therapies directed in modifying its natural history, a need for 'disease modifying antisarcoidosis therapies' [61] . There is a compelling need to explore the potential benefits of a growing number of therapeutics targeting molecules relevant to T-cell activation, Th1 and Th17 immune pathways, important signal transduction pathways, and the ubiquitin-proteasome system. The growing number of therapeutics to treat diseases that share common pathogenic mechanisms with sarcoidosis -such as rheumatoid arthritis, Crohn's disease, and psoriasis -offer an excellent opportunity to explore these biologic agents as novel therapies in patients with sarcoidosis.
